Concepedia

Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5•MTA Complex for the Treatment of <i>MTAP</i> -Deleted Cancers

Christopher R. Smith, Ruth Aranda, Thomas P. Bobinski, David M. Briere, Aaron C. Burns, James G. Christensen, Jeffery Clarine, Lars D. Engstrom, Robin J. Gunn, Anthony Ivetac,

Journal of Medicinal Chemistry · 2022 · 151 citations · 28 references

DOIFull text

Open access

Concepts

Abstract

.

References

28

Oncogenic Signaling Pathways in The Cancer Genome Atlas

Francisco Sánchez-Vega, Marco Mina, Joshua Armenia et al. · Cell · 2018 · 3.4K citations · Full text

, , +17

Physiochemical drug properties associated with in vivo toxicological outcomes

Jason D. Hughes, Julian Blagg, David A. Price et al. · Bioorganic & Medicinal Chemistry Letters · 2008 · 973 citations

, , +14

<i>MTAP</i> deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells

Gregory V. Kryukov, Frederick H. Wilson, Jason R. Ruth et al. · Science · 2016 · 653 citations

, , +17

Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5

Konstantinos J. Mavrakis, E. Robert McDonald, Michael R. Schlabach et al. · Science · 2016 · 580 citations

, , +16

A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models

Elayne Chan-Penebre, Kristy G. Kuplast, Christina R. Majer et al. · Nature Chemical Biology · 2015 · 546 citations

, , +8